CN103108628B - 用于输注b型羊毛硫抗生素的制剂 - Google Patents

用于输注b型羊毛硫抗生素的制剂 Download PDF

Info

Publication number
CN103108628B
CN103108628B CN201180038723.5A CN201180038723A CN103108628B CN 103108628 B CN103108628 B CN 103108628B CN 201180038723 A CN201180038723 A CN 201180038723A CN 103108628 B CN103108628 B CN 103108628B
Authority
CN
China
Prior art keywords
formulation
compound
lantibiotic
type
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180038723.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108628A (zh
Inventor
A·N·阿普尔亚德
S·N·沃德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacta Biosystems Ltd
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of CN103108628A publication Critical patent/CN103108628A/zh
Application granted granted Critical
Publication of CN103108628B publication Critical patent/CN103108628B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180038723.5A 2010-08-11 2011-08-09 用于输注b型羊毛硫抗生素的制剂 Expired - Fee Related CN103108628B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1013513.5A GB201013513D0 (en) 2010-08-11 2010-08-11 Formulations
GB1013513.5 2010-08-11
PCT/GB2011/001191 WO2012020219A2 (en) 2010-08-11 2011-08-09 Formulations for infusion of type b lantibiotics

Publications (2)

Publication Number Publication Date
CN103108628A CN103108628A (zh) 2013-05-15
CN103108628B true CN103108628B (zh) 2015-08-05

Family

ID=42931511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180038723.5A Expired - Fee Related CN103108628B (zh) 2010-08-11 2011-08-09 用于输注b型羊毛硫抗生素的制剂

Country Status (9)

Country Link
US (1) US9192569B2 (https=)
EP (1) EP2603204A2 (https=)
JP (1) JP5865374B2 (https=)
CN (1) CN103108628B (https=)
CA (1) CA2807206A1 (https=)
EA (1) EA024344B1 (https=)
GB (1) GB201013513D0 (https=)
MX (1) MX2013001470A (https=)
WO (1) WO2012020219A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CN109620979B (zh) * 2018-12-29 2020-09-01 福建师范大学 低离子休克提高氨基糖苷类抗生素杀灭持留菌效率的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
WO2007083112A2 (en) * 2006-01-17 2007-07-26 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae
US20100179207A1 (en) * 2009-01-14 2010-07-15 Novacta Biosystems Limited Compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013513A (en) 1963-03-25 1965-12-15 Watney Combe Reid & Co Ltd Improvements in and relating to hopping beer
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (https=) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0700998B1 (en) 1994-09-12 2003-11-26 Aventis Pharma Deutschland GmbH Recombinant mersacidin and a method for production
CN1138560C (zh) 1995-06-23 2004-02-18 Ambi股份有限公司 控制对抗生素耐药的革兰氏阳性细菌的方法和治疗感染的方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
JP2006502713A (ja) 2002-10-10 2006-01-26 モリケム メディシンズ， インコーポレイテッド デュラマイシンをコードする核酸
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
ES2281808T3 (es) 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
US20050271650A1 (en) 2004-02-17 2005-12-08 Cellmatrix, Inc. Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
KR20120038021A (ko) 2006-10-27 2012-04-20 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
WO2010058238A1 (en) 2008-11-24 2010-05-27 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
JP5852966B2 (ja) * 2010-02-02 2016-02-03 ノヴァクタ バイオシステムズ リミティッド ランチビオティックの塩
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
US20130171252A1 (en) 2010-07-14 2013-07-04 Novacta Biosystems Limited Formulation Comprising a Type B Lantibiotic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
WO2007083112A2 (en) * 2006-01-17 2007-07-26 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae
US20100179207A1 (en) * 2009-01-14 2010-07-15 Novacta Biosystems Limited Compounds

Also Published As

Publication number Publication date
MX2013001470A (es) 2013-05-14
WO2012020219A3 (en) 2012-04-05
JP5865374B2 (ja) 2016-02-17
CN103108628A (zh) 2013-05-15
JP2013533304A (ja) 2013-08-22
WO2012020219A2 (en) 2012-02-16
US20130137630A1 (en) 2013-05-30
EP2603204A2 (en) 2013-06-19
GB201013513D0 (en) 2010-09-22
US9192569B2 (en) 2015-11-24
EA201291463A1 (ru) 2013-07-30
EA024344B1 (ru) 2016-09-30
CA2807206A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
US20220354786A1 (en) Suspension comprising a protein particle suspended in a non-aqueous vehicle
KR102345084B1 (ko) 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제
CN104000783B (zh) 头孢喹肟脂质体
IL270686B (en) Derivatives of glycopeptides and their uses
RS60119B1 (sr) Poboljšane formulacije levosimendana za intravensko davanje kao infuzija ili injekcija i infuzioni koncentrat
CN103108628B (zh) 用于输注b型羊毛硫抗生素的制剂
CN117337182A (zh) 一种水通道蛋白抑制剂的药物组合物及其制备方法
DE102004022927A1 (de) 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
RU2315623C2 (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата
JPH03193735A (ja) グリコペプチド系抗生物質の安定化組成物
CN109310783B (zh) 环糊精-帕比司他加合物
KR20220034053A (ko) 재조합 단백질의 안정적인 제형
US20210101929A1 (en) Method for stabilizing protein comprising formulations by using a meglumine salt
CN115475230B (zh) 一种卡非佐米纳米乳混悬冻干制剂及其制备方法
KR101801177B1 (ko) 안정한 노카티아신 동결건조 주사 제제
CN102648978A (zh) 一种稳定的蛋白药物制剂及其制备方法
CN112601541B (zh) 口服给药的生物聚合物制剂
EP4559483A1 (en) Hyaluronic acid derivative drug composition and drug composition
CN109078001A (zh) 一种新型万古霉素纳米脂质体组合物及其制备方法
WO2023171588A1 (ja) 抗菌薬を含有するｐｌｇａ製剤
WO2024139226A1 (zh) 含白蛋白结合型优替德隆纳米粒的药物组合物及其制备方法
TW202600172A (zh) 載體組合物
WO2025017561A1 (en) A peptide composition and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150805

Termination date: 20160809

CF01 Termination of patent right due to non-payment of annual fee